We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ariosa Diagnostics Announces Completion of Laboratory-Developed Test Study for Prenatal Test
News

Ariosa Diagnostics Announces Completion of Laboratory-Developed Test Study for Prenatal Test

Ariosa Diagnostics Announces Completion of Laboratory-Developed Test Study for Prenatal Test
News

Ariosa Diagnostics Announces Completion of Laboratory-Developed Test Study for Prenatal Test

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ariosa Diagnostics Announces Completion of Laboratory-Developed Test Study for Prenatal Test"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The multi-national study represents the largest clinical study performed to date for non-invasive prenatal detection of common fetal trisomies. The test utilizes a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood. Additionally, information about the company's proprietary biochemistry and algorithm platforms, which work together to efficiently analyze patient samples in order to provide individualized risk scores, will be presented at the 2012 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Charlotte, N.C.

"The completion of our validation study is an important milestone as we prepare to bring the Harmony Prenatal Test to market," said Ken Song, MD, chief executive officer at Ariosa Diagnostics. "The Harmony Prenatal Test's performance is the largest study to date using cell-free DNA technology and supports findings from our previous studies recently published in the American Journal of Obstetrics and Gynecology and Prenatal Diagnosis demonstrating highly accurate fetal trisomy detection."

At the upcoming ACMG meeting, additional data on Ariosa's technology will be shared during an oral platform presentation (Molecular session) titled, "Non-Invasive Fetal Aneuploidy Detection in Cell-free DNA from Maternal Blood Using Digital Analysis of Selected Regions (DANSR(TM)) and the Fetal-fraction Optimized Risk of Trisomy Evaluation (FORTE(TM)) Algorithm" on Thursday, March 29, 2012 from 8:30 to 8:45 a.m. at the Charlotte Convention Center.

Advertisement